GRI · GRI Bio, Inc.

NasdaqHealthcareBiotechnology

Gri Bio Inc Is A Clinical-Stage Biotech Company Focused On Discovering, Developing, And Commercializing Therapies Targeting Serious Diseases Associated With Dysregulated Immune Responses That To Inflammatory, Fibrotic, And Autoimmune Disorders. Gri Bio'S Program, Gri-0621, Is A Small Molecule Rar-Beta And Gamma Dual Agonist That Inhibits The Activity Of Human Nkt I Cells, Returning The Immune System To Homeostasis. It Is Also An Oral Formulation Of Tazarotene, A Synthetic Rar-Beta And Gamma Selective Agonist For The Topical Treatment Of Psoriasis And Acne. The Company'S Other Product Candidate Gri-0803 Is A Novel Oral Agonist Of Type 2 Natural Killer T (Type 2 Nkt) Cells Which Can Be A Potential Treatment For Autoimmune Disorders.

HealthcareNasdaqUSVery Low Float

$11.03

+33.3% latest move

Price & move as of the most recent catalyst (Jan 7) — not a live quote.

FLOAT

1.7M

FREE FLOAT %

79%

SHARES O/S

2.2M

MARKET CAP

$3.4M

EXCHANGE

Nasdaq

COUNTRY

GRI Catalyst History

Regulatory and ClinicalJan 7, 2026 · 6:58pm ET

GRIGRI Bio, Inc. Common Stock

GRI Bio Strengthens Clinical Proof-of-Concept for GRI-0621 with Positive Phase 2a Study Data

GRI Bio announced additional positive data from a Phase 2a study in Idiopathic Pulmonary Fibrosis.

Be early on the next GRI spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

GRI · GRI Bio, Inc.

GRI Catalyst History

GRI Bio Strengthens Clinical Proof-of-Concept for GRI-0621 with Positive Phase 2a Study Data

GRI Bio Strengthens Clinical Proof-of-Concept for GRI-0621 with Positive Phase 2a Study Data

GRI Bio Reports Interim 6-Week Lung Function Results for GRI-0621 in Phase 2a IPF Study

GRI Bio Reports Interim 6-Week Lung Function Results for GRI-0621 in Phase 2a IPF Study